TY - JOUR
T1 - Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease
AU - Hahm, Eunsil
AU - Wei, Changli
AU - Fernandez, Isabel
AU - Li, Jing
AU - Tardi, Nicholas J.
AU - Tracy, Melissa
AU - Wadhwani, Shikha
AU - Cao, Yanxia
AU - Peev, Vasil
AU - Zloza, Andrew
AU - Lusciks, Jevgenijs
AU - Hayek, Salim S.
AU - O'Connor, Christopher
AU - Bitzer, Markus
AU - Gupta, Vineet
AU - Sever, Sanja
AU - Sykes, David B.
AU - Scadden, David T.
AU - Reiser, Jochen
N1 - Publisher Copyright:
© 2017 Nature America, Inc., part of Springer Nature. All rights reserved.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Excess levels of protein in urine (proteinuria) is a hallmark of kidney disease that typically occurs in conjunction with diabetes, hypertension, gene mutations, toxins or infections but may also be of unknown cause (idiopathic). Systemic soluble urokinase plasminogen activator receptor (suPAR) is a circulating factor implicated in the onset and progression of chronic kidney disease (CKD), such as focal segmental glomerulosclerosis (FSGS). The cellular source(s) of elevated suPAR associated with future and progressing kidney disease is unclear, but is likely extra-renal, as the pathological uPAR is circulating and FSGS can recur even after a damaged kidney is replaced with a healthy donor organ. Here we report that bone marrow (BM) Gr-1 lo immature myeloid cells are responsible for the elevated, pathological levels of suPAR, as evidenced by BM chimera and BM ablation and cell transfer studies. A marked increase of Gr-1 lo myeloid cells was commonly found in the BM of proteinuric animals having high suPAR, and these cells efficiently transmit proteinuria when transferred to healthy mice. In accordance with the results seen in suPAR-associated proteinuric animal models, in which kidney damage is caused not by local podocyte-selective injury but more likely by systemic insults, a humanized xenograft model of FSGS resulted in an expansion of Gr-1 lo cells in the BM, leading to high plasma suPAR and proteinuric kidney disease. Together, these results identify suPAR as a functional connection between the BM and the kidney, and they implicate BM immature myeloid cells as a key contributor to glomerular dysfunction.
AB - Excess levels of protein in urine (proteinuria) is a hallmark of kidney disease that typically occurs in conjunction with diabetes, hypertension, gene mutations, toxins or infections but may also be of unknown cause (idiopathic). Systemic soluble urokinase plasminogen activator receptor (suPAR) is a circulating factor implicated in the onset and progression of chronic kidney disease (CKD), such as focal segmental glomerulosclerosis (FSGS). The cellular source(s) of elevated suPAR associated with future and progressing kidney disease is unclear, but is likely extra-renal, as the pathological uPAR is circulating and FSGS can recur even after a damaged kidney is replaced with a healthy donor organ. Here we report that bone marrow (BM) Gr-1 lo immature myeloid cells are responsible for the elevated, pathological levels of suPAR, as evidenced by BM chimera and BM ablation and cell transfer studies. A marked increase of Gr-1 lo myeloid cells was commonly found in the BM of proteinuric animals having high suPAR, and these cells efficiently transmit proteinuria when transferred to healthy mice. In accordance with the results seen in suPAR-associated proteinuric animal models, in which kidney damage is caused not by local podocyte-selective injury but more likely by systemic insults, a humanized xenograft model of FSGS resulted in an expansion of Gr-1 lo cells in the BM, leading to high plasma suPAR and proteinuric kidney disease. Together, these results identify suPAR as a functional connection between the BM and the kidney, and they implicate BM immature myeloid cells as a key contributor to glomerular dysfunction.
UR - http://www.scopus.com/inward/record.url?scp=85004045051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85004045051&partnerID=8YFLogxK
U2 - 10.1038/nm.4242
DO - 10.1038/nm.4242
M3 - Article
C2 - 27941791
AN - SCOPUS:85004045051
SN - 1078-8956
VL - 23
SP - 100
EP - 106
JO - Nature Medicine
JF - Nature Medicine
IS - 1
ER -